$INSY Saturday morning. The week went well for INS
Post# of 212
INSYS Therapeutics appears to be managing these difficult times with a true professional approach. They are focusing on the strength of the company. Its R&D plus its current approved product lines are solid and have great value to the market. Presumably, they have planned for the next media assault of its former CEO, et al and will be prepared to support the stock and maintain its future value.
I remain very supportive of this stock and believe it to be a outstanding investment.